Keros Therapeutics, Inc.
General ticker "KROS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $672.4M (TTM average)
Keros Therapeutics, Inc. follows the US Stock Market performance with the rate: 8.1%.
Estimated limits based on current volatility of 3.8%: low 17.43$, high 18.83$
Factors to consider:
- Total employees count: 169 (+24.3%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Dependence on product candidates, Limited operating history, Regulatory and compliance, Market competition
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.18$, 40.45$]
- 2025-12-31 to 2026-12-31 estimated range: [11.13$, 31.30$]
Financial Metrics affecting the KROS estimates:
- Negative: with PPE of -3.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -25.85 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.31 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term KROS quotes
Long-term KROS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.15MM | $3.55MM |
| Operating Expenses | $114.79MM | $170.09MM | $214.38MM |
| Operating Income | $-114.79MM | $-169.94MM | $-210.83MM |
| Non-Operating Income | $10.11MM | $16.95MM | $23.78MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $87.27MM | $135.26MM | $173.63MM |
| Income(Loss) | $-104.68MM | $-152.99MM | $-187.05MM |
| Taxes | $0.00MM | $0.00MM | $0.30MM |
| Profit(Loss)* | $-104.68MM | $-152.99MM | $-187.35MM |
| Stockholders Equity | $277.42MM | $332.21MM | $571.55MM |
| Assets | $306.78MM | $370.02MM | $615.89MM |
| Operating Cash Flow | $-70.06MM | $-124.51MM | $-160.87MM |
| Capital expenditure | $1.24MM | $2.46MM | $1.93MM |
| Investing Cash Flow | $-1.24MM | $-2.46MM | $-1.93MM |
| Financing Cash Flow | $120.31MM | $178.96MM | $391.82MM |
| Earnings Per Share** | $-4.15 | $-5.20 | $-5.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.